Last updated: February 25, 2026
What is the Market Size for NDC 81952-0126?
The drug identified by NDC 81952-0126 is Nivolumab (Opdivo), a PD-1 immune checkpoint inhibitor used primarily for various cancers, including melanoma, lung cancer, and renal cell carcinoma.
Indications and Usage
- Melanoma, metastatic or unresectable
- Non-small cell lung cancer (NSCLC)
- Renal cell carcinoma
- Other indications, including head and neck squamous cell carcinoma and Hodgkin lymphoma
Market Size (2023 Estimates)
- Global oncology drug market valuation: approximately $150 billion
- Nivolumab's share: estimated at 10%, roughly $15 billion annually
- U.S. market share (2023): approximately $7 billion
- Projected growth rate: 10-12% CAGR over the next 5 years
Key Market Drivers
- Expansion of approved indications
- Increasing incidence of target cancers
- Growing adoption in combination therapies
- US approval for first-line treatments in multiple cancers
What are the Price Trends and Projections?
Current Pricing Landscape
- Average wholesale price (AWP): approximately $5,000 to $6,000 per vial
- Cost per treatment course: varies between $100,000 and $200,000 depending on dosing and treatment duration
- Reimbursement rates: linked to CMS and private payers, with negotiated discounts
Price Components
- Administered as intravenous infusion
- Dose based on patient weight (e.g., 240 mg every 2 weeks)
- Treatment duration varies (often 12-24 months)
Price Projection (2024-2028)
| Year |
Estimated Average Price per Treatment Course |
Factors Influencing Price |
| 2024 |
$105,000 |
Patent protections upheld, high demand, limited biosimilar competition |
| 2025 |
$103,000 |
Slight price erosion due to biosimilar entry in other markets |
| 2026 |
$101,000 |
Increased competition, expanding biosimilar pipeline |
| 2027 |
$99,000 |
Price stabilization, more biosimilar launches anticipated |
| 2028 |
$97,000 |
Further biosimilar adoption, payor pressure |
Biosimilar Impact
- Biosimilars for nivolumab are under development in several regions
- Expected to launch in Europe 2025-2026; U.S. approval possible by 2027
- Potential price reductions of 15-25% upon biosimilar entry
Regulatory and Competitive Landscape
Patent and Exclusivity Periods
- Original patent expiry: 2028
- Exclusive marketing rights until then limit biosimilar competition
Competition
- Pembrolizumab (Keytruda) is a primary competitor with a similar indication profile
- Emerging biosimilars and pipeline immunotherapies
Regulatory Developments
- FDA approvals continue expanding nivolumab's indications
- Ongoing clinical trials for combination therapies and new cancer types
Opportunities and Risks
Opportunities
- Growing cancer incidence globally, especially in emerging markets
- Expansion into new indications and combination protocols
- Price optimization through value-based pricing and negotiated discounts
Risks
- Entry of biosimilar competitors lowering prices
- Patent disputes delaying biosimilar introduction
- Reimbursement cuts from payers limiting revenue
Key Takeaways
- Nivolumab remains a dominant immunotherapy with a multi-billion dollar global market.
- Prices are high but may decline gradually with biosimilar market entry.
- The main growth driver is increasing indications and expanding use in combination therapies.
- Patent expirations in 2028 pose imminent competitive threats.
FAQs
1. What factors most influence nivolumab's price?
Patent protection, manufacturing costs, competition from biosimilars, and payer negotiations.
2. How will biosimilar entry affect pricing?
It is expected to reduce prices by 15-25%, impacting revenue margins.
3. What are the key indications driving demand?
Melanoma, non-small cell lung cancer, renal cell carcinoma, and head and neck cancers.
4. When will biosimilars likely enter the U.S. market?
Potentially starting in 2027, following approvals in Europe.
5. What is the outlook for nivolumab's market share?
It will likely remain significant but decline gradually with biosimilar competition and new therapies.
References
- IQVIA (2023). Global Oncology Market Report.
- FDA (2023). Approved Cancer Treatments.
- CMS (2023). Reimbursement Policies for Oncology Drugs.
- EvaluatePharma (2023). Oncology Drug Market Trends.
- European Medicines Agency (2023). Biosimilar Approvals.
